Predictors of Treatment Failure with Sofosbuvir/Daclatasvir Regimen for 12 Weeks in Patients with Chronic HCV in Egypt

Ahmed Tawheed *

Endemic Medicine Department, Helwan University, Egypt.

Mohamed El Kassas

Endemic Medicine Department, Helwan University, Egypt.

Amr El Fouly

Endemic Medicine Department, Helwan University, Egypt.

Gamal Esmat

Endemic Medicine Department, Cairo University, Egypt.

*Author to whom correspondence should be addressed.


Background: Hepatitis C virus HCV infection is one of the main causes of chronic liver disease worldwide, Egypt has the highest national-level HCV prevalence in the world, Sofosbuvir/ Daclatasvir (SOF/DAC) regimen widely used to treat HCV infection in Egypt.

Aims: to identify the predictors of treatment failure with Sofosbuvir/Daclatasvir regimen for 12 weeks in HCV Egyptian patients.

Methodology: A retrospective cohort, we investigated the predictors of treatment failure in 2300 HCV patients received the SOF/DAC regimen in Egypt.

Results: Patients who completed the treatment and follow up visits were 2079 patients,4 patients stopped treatment due to side effects, 35 due to incompliance and 182 patients missed their follow up visits after treatment, out of the 2079 patients 2043 (98.3%) patients responded to treatment with SVR12 and just 36 (1.7%) patients had treatment failure, presence of Hypertension (p=0.001), Diabetes Miletus (p=0.001), ALT level >51 (p=0.013) , AST level >60 (p=0.002), AFP > 6 (p=0.000) and abnormal liver echo-pattern all were found to have an impact on SVR12 rates, some other factors were found to be insignificant as age, sex, BMI, special habits, liver function tests, haemoglobin, total leucocytic count and serum creatinine, by multivariate analysis AFP was found to be the strongest predictor of treatment failure with cut off value >6 with sensitivity 66.67% and specificity 77.31%.

Conclusion: This study shows that ALT, AST, AFP, Abnormal Liver Echo-pattern and the Presence of Diabetes Miletus or Hypertension were found to affect SVR rates, but the strongest predictor was AFP level with a cutoff value of >6.

Keywords: Hepatitis C virus, HCV, Sofosbuvir, Daclatasvir, DAAs, predictors, SVR12

How to Cite

Tawheed, A., El Kassas, M., El Fouly, A., & Esmat, G. (2023). Predictors of Treatment Failure with Sofosbuvir/Daclatasvir Regimen for 12 Weeks in Patients with Chronic HCV in Egypt. International Journal of TROPICAL DISEASE & Health, 44(1), 57–64.


Download data is not yet available.


Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection. 2011;17:107–115.

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al., Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015 Jan;61(1):77-87.

DOI: 10.1002/hep.27259

Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45-53.


Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study. Hepatology. 2007;46(5):1350-1356.


El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K, et al., National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat. 2017 Apr;24(4):262-267.

DOI: 10.1111/jvh.12668. Epub 2017 Feb 1. PMID: 28145032.

Cavalcante L, Lyra A. Predictive factors associated with hepatitis C antiviral therapy response. World Journal of Hepatology. 2015;7(12):1617-1631

Youssef NF, El Kassas M, Farag A, Shepherd A. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: A prospective observational study in Egypt. BMC Gastroenterol. 2017 Jan 21;17(1):18.

DOI: 10.1186/s12876-017-0581-1.

EASL 2016

Asselah T. Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacy. Journal of Hepatology. 2014;61(2):435-438.

Gamal N, Gitto S, Andreone P. Efficacy and safety of Daclatasvir in hepatitis C: An Overview. J ClinTranslHepatol. 2016;4(4):336-344.

El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016 Dec;15(12):1643-1652.

DOI: 10.1080/14740338.2017.1240781.

Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, et al., Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015 Sep;63(3):581-5.

DOI: 10.1016/j.jhep.2015.04.023..

El-Khayat H, Fouad Y, Mohamed HI, El-Amin H, Kamal EM, Maher M, Risk A. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther. 2018 Mar;47(5):674-679.

Doi: 10.1111/apt.14482.

Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, et al., Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018 Feb;47(3):421-431.

DOI: 10.1111/apt.14428.

Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, et al., Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017 Jun;24(6):454-463.

DOI: 10.1111/jvh.12663

Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer Net al., Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort. Hepat Med. 2017 Dec 18;9:67-73.

DOI: 10.2147/HMER.S149578

Gastaldi G, Goossens N, Clément S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res. 2017;8(2):149-159.


EASL 2014.

Bialecki S and Di Bisceglie Diagnosis of hepatocellular carcinoma HPB (Oxford). 2005,(7)1:26-34.

Chen TM, Huang PT, Tsai MH Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis c, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterolhepatol. 2007;22(5):669–675.